IntroductionVarious forms of vitamin D and factors involved in their metabolism can play a role in the etiopathogenesis of metabolic disorders. This paper aims to define the relationship between concentration of the hydroxylated form of vitamin D (25(OH)D), the fraction of free and bioavailable vitamin D, and of vitamin D binding protein (VDBP) levels on the one hand and the prevalence of metabolic syndrome components on the other.Material and methodsThe studies were conducted on 79 people, including 52 with metabolic syndrome (MetS+) and 27 without it (MetS–). Biochemical measurements (lipid profile, glycemia, 25(OH)D, VDBP, albumin, calcium, parathyroid hormone) were performed, concentration of free and bioavailable vitamin D was mathematically calculated, and anthropometric and blood pressure measurements were taken.ResultsThe mean ± SD concentration of 25(OH)D among MetS+ individuals (41.90 ±13.12 nmol/l) was lower (p < 0.0001) than among the MetS– group (66.09 ±18.02 nmol/l). Differences between groups were observed in relation to medians/means of concentrations of free and bioavailable vitamin D (p < 0.0001) but not in the case of VDBP. In the entire study population, 25(OH)D correlated with all metabolic syndrome components, whereas its free and bioavailable fraction correlated with particular components of the syndrome. In the MetS+ group, VDBP concentration negatively correlated with body mass index (p = 0.037) and levels of diastolic pressure (p = 0.022). In the case of the MetS– group, the free fraction of vitamin D negatively correlated with triglyceridemia (p = 0.049).ConclusionsThe evaluation of various forms of vitamin D and VDBP in different population groups seems to have significant clinical value in evaluating the prevalence of metabolic disorders.

No abstract

Introduction. The population of elderly people is exposed to the development of disorders related to physiological ageing, as well as relatively common diseases occurring in the old age period. The gastrointestinal diseases, which reduce the absorption of many nutrients, are more frequent in the elderly compared to younger population.Material and Methods. In the study was attempted the assess of conditions of dietary supplementation by 60 years old people or older (60+). The comparisons of results were obtained with relation to young adults and middle aged persons (18–58 years). The survey was conducted with 368 adult, including 123 respondents over 60 years old and 245 younger people.Results. The study has been shown that dietary supplements were used by 64.2% of elderly people and 59.6% of younger respondents. The most common source of knowledge about dietary supplements in the elderly was a physician (40.7%) in contrast to younger population, where dominated the Internet (60.0%). The main reason of supplementation in the 60+ group was an enhancement the immune system, while in younger population it was important to improve the appearance of skin, hair and nails. The most common components of supplements, which were used in the elderly population, were vitamin C (32.5%) and magnesium (28.5%) compared to younger group where the most popular were vitamin D (22.5%) and magnesium (19.2%).Conclusions. The overuse of supplements, especially among the elderly, can lead to disability, therefore it is important to expand the education about side effects the improperly using of dietary supplements.

Introduction The aim of our study was to determine the relationship between neuropeptide B (NPB), neuropeptide W (NPW), nutritional and antioxidant status and selected fat- and bone-derived factors in type 1 diabetes mellitus (T1DM) treated using pens (T1DM pen group) or insulin pumps (T1DM pump group) in order to investigate the potential role of NPB and NPW in the clinical outcomes of T1DM. Material and methods Fifty-eight patients with T1DM and twenty-five healthy controls (CONTR) participated in the study. Assessments of NPB, NPW, total antioxidant status (TAS), leptin, adiponectin, osteocalcin, and free soluble receptor activator for nuclear factor κB (free sRANKL) were conducted. Results NPB, NPW, leptin, and TAS were lower (by 33%, p < 0.013; 34%, p < 0.008; 290%, p < 0.00004; 21%, p < 0.05; respectively), while adiponectin was by 51% higher ( p < 0.006) in T1DM vs. CONTR, while osteocalcin and free sRANKL levels were similar in both groups. NPW was lower in the T1DM pen group both vs. the T1DM pump group (36% lower, p < 0.0009) and vs. the CONTR group (35% lower, p < 0.002). In the T1DM pen group, but not in the T1DM pump group or the CONTR group, the Cole index and TAS levels explain (besides NPB) the variation in NPW values. ROC curves showed that serum levels of leptin, adiponectin, NPB and NPW (but not osteocalcin or free sRANKL) were predictive indicators for T1DM. Conclusions Measurements of NPB and NPW, besides leptin and adiponectin, are worth considering in the detailed prognosis of nutritional status in T1DM, primarily in the T1DM pen-treated population.

Omentin is one of the few adipokines with potentially beneficial metabolic effects. The main aim of this study was to determine the association between serum omentin-1 levels and the occurrence of central obesity and abnormal glucose tolerance, taking into account gender. The study involved 88 participants aged 30–60, including 47 women and 41 men. Two subgroups among the obese subjects were distinguished—those with normal and abnormal glucose tolerance. Anthropometric and biochemical examinations and blood pressure measurements were performed. Omentin-1 concentrations were significantly lower among patients with obesity compared to those without obesity (p = 0.027) and, similarly, comparing men with abnormal glucose tolerance with men with normal glucose tolerance (p = 0.035). In contrast, no such pattern was observed in women. The multivariable regression model showed a significant effect of gender status and important factors of tissue insulin sensitivity, such as OGGT results, WHR and amount of body fat, on the variability of serum omentin-1 concentration in the entire study population (R2adj. = 13.7%; p = 0.003). High omentin-1 levels found in men with obesity and normal glucose tolerance suggest that omentin-1 protects against metabolic disorders associated with obesity in the male population.